Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Online tool shows co-payments for cyclosporine
Allergan has launched a new digital tool designed to help eye-care professionals determine patient co-payments when prescribing cyclosporine ophthalmic emulsion 0.05% (Restasis) to manage dry eye.
Irvine, CA-Allergan has launched a new digital tool designed to help eye-care professionals determine patient co-payments when prescribing cyclosporine ophthalmic emulsion 0.05% (Restasis) to manage dry eye.
Using a computer or smartphone, ophthalmologists and other eye-care professionals can enter a patient’s ZIP code and then obtain the average co-pay for the health plans that have the biggest enrollments in the geographic area.
The tool is available at www.restasiscopay.com.
Related Videos
Related Content
